The UK and US have forged a major bilateral deal that will preserve zero import taxes on British pharmaceutical shipments going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This commitment secures that import taxes on these key products will remain at zero for a timeframe of the next three years.
This agreement comes after previous statements to dramatically increase import taxes on patented drug products, with increases floated reaching one hundred percent.
"This deal between the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to transatlantic drug exports," an announcement said.
Economic Significance
Pharmaceuticals constitute one of the Britain's most significant exports to the US, which is clearly the largest buyer for large British pharmaceutical firms.
Export figures indicate that in the 12 months prior to last September, the UK exported drugs valued at over eleven billion pounds to the US. This figure accounted for 17.4% of all goods exports in that span.
"This deal protects employment, stimulates capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a government official stated.
Detailed British Pledges
The deal involves several key changes from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase overall public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates exceeded 20%.
Recent Tensions
This agreement takes place against a ongoing row between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
These tensions were heightened by assertions that US customers were paying several times more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been paused or abandoned, while substantial funding commitments have been announced toward American operations.
One official stated that the NHS must spend more on medicines, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
